Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Co-Diagnostics, Inc. (NASDAQ: CODX).

Full DD Report for CODX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CODX)

Co-Diagnostics CEO to Discuss Strategic Direction in a Lytham Partners' Virtual Presentation and Fireside Chat Event on Thursday, April 19, 2018 at 2:00 pm ET
Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostic testing, announced today that it will discuss the Company’s strategic direction and recent corporate developments on Thursday, April 1...
Source: Business Wire
Date: April, 16 2018 06:30
Co-Diagnostics Files Initial Annual Report on Form 10-K and Updates Corporate Developments
CODX updates on initial six months as a public company Co-Diagnostics, Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced the filing of its initial Annual Report on Form 10-K as a public...
Source: Business Wire
Date: April, 05 2018 06:30
Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing Facility in India
Project moving forward on schedule, with production to begin in Q3 2018 Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an update on the Joint Venture (“JV”...
Source: Business Wire
Date: March, 22 2018 06:30
Co-Diagnostics Inc Announces Positive Results from Co-Primers(TM) Technology in Multiplex Tests for SNP Detection
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that ongoing research and development activities of the Compa...
Source: Business Wire
Date: February, 28 2018 06:30
Co-Diagnostics, Inc. Ships Product to India for Validation Study
Shipment includes 10,000 tests to be sold as Research Use Only by Joint Venture Co-Diagnostics, Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today a product shipment to Indi...
Source: Business Wire
Date: February, 21 2018 06:30
Co-Diagnostics, Inc. Initiates Vector Control Program in Dominican Republic
Program received enthusiastically by regional Ministries of Health Co-Diagnostics, Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today the completion of a sales and validation tri...
Source: Business Wire
Date: January, 30 2018 06:30
Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility
Laboratory will meet CGMP Requirements of FDA; Will be BSL-2 to allow enhanced in-house verification and validation activities Co-Diagnostics, Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, ann...
Source: Business Wire
Date: December, 19 2017 06:30
Co-Diagnostics, Inc. Announces Sale of Molecular Diagnostic Tests, Including Zika Virus, to Major Caribbean Laboratory
Co-Diagnostics, Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that a major laboratory in the Caribbean Basin has completed its first purchase of the Company’s tests. The...
Source: Business Wire
Date: December, 12 2017 06:30
Co-Diagnostics (CODX) Presents At Lytham Partners Virtual Investor Conference - Slideshow
The following slide deck was published by Co-Diagnostics in conjunction with this Read more ...
Source: SeekingAlpha
Date: December, 04 2017 13:16
Co-Diagnostics, Inc. to Present at the Lytham Partners Virtual Investor Conference on November 30, 2017 at 2:00 p.m. ET
Management to Review Investor Presentation and Conduct Q&A; Replay Available on Demand Co-Diagnostics, Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced that Dwight Egan, ch...
Source: Business Wire
Date: November, 22 2017 15:11

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-181.701.711.821.708,724
2018-05-171.701.711.821.708,724

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-136963,14622.1233Cover
2018-08-1022,2260.0898Cover
2018-08-091001,5006.6667Cover
2018-08-083,2004,26575.0293Short
2018-08-07729729100.0000Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CODX.


About Co-Diagnostics, Inc. (NASDAQ: CODX)

Logo for Co-Diagnostics, Inc. (NASDAQ: CODX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CODX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 11 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 11 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 28 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 28 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: November, 14 2017
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: November, 14 2017
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 25 2017
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 25 2017
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: July, 14 2017

       

       


      Daily Technical Chart for (NASDAQ: CODX)

      Daily Technical Chart for (NASDAQ: CODX)


      Stay tuned for daily updates and more on (NASDAQ: CODX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CODX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CODX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CODX and does not buy, sell, or trade any shares of CODX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/